Older Adult Training Study With Creatine and CLA

Creatine Monohydrate and Conjugated Linoleic Acid Improve Strength and Body Composition Following Resistance Exercise in Older Adults

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00473902

Acronym

OTR

Enrollment

Registered

2007-05-16

Start date

2003-08-31

Completion date

2004-09-30

Last updated

2007-05-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sarcopenia

Brief summary

We examined whether creatine monohydrate (CrM) and conjugated linoleic acid (CLA) could enhance strength gains and improve body composition (i.e., increase fat-free mass (FFM); decrease body fat) following resistance exercise training in older adults (\> 65 y). Our study hypothesized that administering CrM and CLA would yield greater strength and body composition benefits than the placebo group over the six months of resistance exercise

Detailed description

Men (N=19) and women (N=20) completed six months of resistance exercise training with Creatine Monohydrate (5g/d) + Conjugated Linoleic Acid (6g/d) or placebo with randomized, double-blind, allocation.Outcomes included; strength and muscular endurance, functional tasks, body composition (DEXA scan), blood tests (lipids, liver function, CK, glucose, systemic inflammation markers (IL-6, C-reactive protein)), urinary markers of compliance (creatine/creatinine), oxidative stress (8-OH-2dG, 8-isoP) and bone resorption (Ν-telopeptides).

Interventions

BEHAVIORALTraining

DRUGCreatine Monohydrate, Conjugated Linoleic Acid

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

65 Years to 85 Years

Healthy volunteers

Yes

Inclusion criteria

* Healthy, * Ambulatory, * Recreationally active, * Community dwelling

Exclusion criteria

* Evidence of coronary heart disease; * Congestive heart disease; * Uncontrolled hypertension; * Chronic obstructive pulmonary disease; * Diabetes mellitus; * Renal failure; * Major orthopedic disability; and * Smoking

Design outcomes

Primary

Measure	Time frame
a. Muscle and bone mass b. Knee extension strength e. Creatine content f. Muscle oxidative capacity g. Aerobic power (oxygen consumption)	six months

Secondary

Measure	Time frame
a. Functional capacity b. Strength with weight machines	six months

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 6, 2026